Efficacy of pazufloxacin mesilate in Legionnaires' disease: a case report and in vitro study of the isolate.
We report here a case of culture-proven Legionnaires' disease successfully treated with intravenous injection of pazufloxacin mesilate (PZFX), a fluoroquinolone newly approved in Japan. The patient was a 51-year-old man hospitalized after a diagnosis of community-acquired pneumonia. Legionella pneumophila SG1 was isolated from the patient's bronchoalveolar lavage (BAL) fluid, and the soluble antigen of the bacterium was detected in the fluid as well. Subsequently, intravenous PZFX was administered for a week and proved markedly effective. An in vitro study confirmed that PZFX had excellent extracellular and intracellular activity against the isolate from the patient. This case suggests that PZFX is an option for treating Legionnaires' disease.
Higa
Futoshi
F
Department of Internal Medicine and Infectious Diseases, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, 903-0215, Japan. fhiga@med.u-ryukyu.ac.jp
Shinzato
Takashi
T
Toyama
Masato
M
Haranaga
Shusaku
S
Furugen
Makoto
M
Tateyama
Masao
M
Kawakami
Kazuyoshi
K
Saito
Atsushi
A
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D016952:Legionella pneumophila; D007877:Legionnaires' Disease / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D010078:Oxazines; C078052:pazufloxacin